Evidence map›Paper›PMID 32888253›Full record

ArticleCancer communications (London, England)2020

Proteomics identifies EGF-like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor-positive glioma.

Fei-Yi-Fan Wang, Si-Yi Wang-Gou, Hang Cao, Nian Jiang, Qi Yang, Qi Huang, Chun-Hai Huang, Xue-Jun Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fei-Yi-Fan WangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.ORCID 0000-0002-4522-0264
Si-Yi Wang-GouDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.
Hang CaoDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.
Nian JiangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.
Qi YangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.
Qi HuangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.
Chun-Hai HuangDepartment of Neurosurgery, the First Affiliated Hospital of Jishou University, Jishou, Hunan, 416000, P. R. China.
Xue-Jun LiDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.ORCID 0000-0001-6406-4423
Central South University · CNJishou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioma, the most frequent primary tumor of the central nervous system, has poor prognosis. The epidermal growth factor receptor (EGFR) pathway and angiogenesis play important roles in glioma growth, invasion, and recurrence. The present study aimed to use proteomic methods to probe into the role of the EGF-EGFR-angiogenesis axis in the tumorigenesis of glioma and access the therapeutic efficacy of selumetinib on glioma.

methodsProteomic profiling was used to characterize 200 paired EGFR-positive and EGFR-negative glioma tissues of all pathological types. The quantitative mass spectrometry data were used for systematic analysis of the proteomic profiles of 10 EGFR-positive and 10 EGFR-negative glioma cases. Consensus-clustering analysis was used to screen target proteins. Immunofluorescence analysis, cell growth assay, and intracranial xenograft experiments were used to verify and test the therapeutic effect of selumetinib on glioma.

resultsAdvanced proteomic screening demonstrated that the expression of EGF-like domain multiple 7 (EGFL7) was higher in EGFR-positive tumor tissues than in EGFR-negative tumor tissues. In addition, EGFL7 could act as an activator in vitro and in vivo to promote glioma cell proliferation. EGFL7 was associated strongly with EGFR and prognosis. EGFL7 knockdown effectively suppressed glioma cell proliferation. Selumetinib treatment showed tumor reduction effect in EGFR-positive glioblastoma xenograft mouse model.

conclusionsEGFL7 is a potential diagnostic biomarker and therapeutic target of glioma. Selumetinib could target the EGFR pathway and possibly improve the prognosis of EGFR-positive glioma.

Indexed as

Calcium-Binding ProteinsEGF Family of ProteinsEpidermal Growth FactorGliomaAdultAnimalsBenzimidazolesCell MovementEndothelial Growth FactorsErbB ReceptorsFemaleHumansMaleMiceNeoplasm Recurrence, LocalProteomicsAZD 6244BenzimidazolesCalcium-Binding ProteinsEGF Family of ProteinsEGFL7 protein, humanEndothelial Growth FactorsEpidermal Growth FactorErbB ReceptorsEGF-like domain multiple 7Epidermal growth factor receptorGliomaProteomicsSelumetinibTargeted therapy

Identifiers

PMID32888253
PMCPMC7571400
OpenAlexW3083362792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.